Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, HOOKIPA Pharma's Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-45.53 Mil. Therefore, HOOKIPA Pharma's EV-to-OCF for today is 0.43.
The historical rank and industry rank for HOOKIPA Pharma's EV-to-OCF or its related term are showing as below:
HOOK'
s EV-to-OCF Range Over the Past 10 Years
Min: -35.28 Med: 0.11 Max: 3.2
Current: 0.43
During the past 8 years, the highest EV-to-OCF of HOOKIPA Pharma was 3.20. The lowest was -35.28. And the median was 0.11.
HOOK's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.41
vs HOOK: 0.43
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
HOOKIPA Pharma's PE Ratio (TTM) for today is calculated as:
HOOKIPA Pharma's share price for today is $1.15.
HOOKIPA Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
HOOKIPA Pharma EV-to-OCF Related Terms
HOOKIPA Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's EV-to-OCF falls into.
HOOKIPA Pharma's current Enterprise Value is $-19.45 Mil.
HOOKIPA Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a EV-to-OCF of 0.43 as of Aug. 06, 2026. This is 291% above median its historical median of 0.11.
Is HOOKIPA Pharma's EV-to-OCF too high?
HOOKIPA Pharma's current EV-to-OCF of 0.43 is 291% above median its 10-year median of 0.11. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's EV-to-OCF compare to COCP and LNAI?
HOOKIPA Pharma's EV-to-OCF of 0.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. HOOKIPA Pharma's current EV-to-OCF is 0.43, which is 291% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current EV-to-OCF of 0.43. The current EV-to-OCF is 0.43, which is 291% above median its 10-year median of 0.11. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current EV-to-OCF is 0.43 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
